"Nintedanib, nov\u00FD inhibitor angiokin\u00E1z, v l\u00E9\u010Db\u011B nemalobun\u011B\u010Dn\u00E9ho karcinomu plic" . . "3"^^ . "LUME-Lung 1 trial; nintedanib; angiogenesis; NSCLC"@en . . "Nintedanib, a new angiokinase inhibitor in the treatment of non-small cell lung cancer"@en . . . "9" . . . . "Nintedanib, nov\u00FD inhibitor angiokin\u00E1z, v l\u00E9\u010Db\u011B nemalobun\u011B\u010Dn\u00E9ho karcinomu plic"@cs . "Salajka, Franti\u0161ek" . . . "1801-1209" . "RIV/00216208:11150/13:10189880!RIV14-MSM-11150___" . "11150" . . "91811" . . "Farmakoterapie" . "Nintedanib, nov\u00FD inhibitor angiokin\u00E1z, v l\u00E9\u010Db\u011B nemalobun\u011B\u010Dn\u00E9ho karcinomu plic"@cs . . . "http://www.farmakoterapie.cz/c3894/nintedanib-novy-inhibitor-angiokinaz-v-lecbe-nemalobunecneho-karcinomu-plic" . "1"^^ . "Suppl 1" . "I" . "Nintedanib, nov\u00FD inhibitor angiokin\u00E1z, v l\u00E9\u010Db\u011B nemalobun\u011B\u010Dn\u00E9ho karcinomu plic" . "Nintedanib is an oral angiokinase inhibitor targeting type 1, 2 and 3 VEGF, type \u03B1 and \u03B2 PDGF, type 1, 2 and 3FGF receptors, and its action also includes FLT3 and Src group receptors. The drug thus results in altered proliferation and survival of three key cellular populations participating in neoangiogenesis - endothelial cells, pericytes and small muscle cells. The administered dose is 250mg nintedanib twice daily, in combination with paclitaxel and carboplatin. Currently the first results are available from phase III trials, specifically LUME-Lung 1 trial that observed significantly extended progression-free survival for combination therapy with nintedanib versus placebo, both for the whole patient population and in patients with either adenocarcinoma or squamous cell carcinoma. The effect of nintedanib on overall survival of the whole patient group was also favourable though not statistically significant."@en . "Nintedanib je peror\u00E1ln\u011B u\u017E\u00EDvan\u00FD inhibitor angiokin\u00E1z, u\u010Dinkuj\u00EDc\u00ED na receptorech pro VEGF typu 1, 2 a 3, PDGF typu \u03B1 a \u03B2, FGF typu 1, 2 a 3, d\u00E1le na receptorech pro FLT3 a skupiny Src. Je tedy ovlivn\u011Bna proliferace a p\u0159e\u017Eit\u00ED t\u0159\u00ED kl\u00ED\u010Dov\u00FDch bun\u011B\u010Dn\u00FDch populac\u00ED z\u00FA\u010Dastn\u011Bn\u00FDch p\u0159i neoangiogenezi - endoteli\u00E1ln\u00EDch bun\u011Bk, pericyt\u016F a bun\u011Bk hladk\u00E9 svaloviny. Pod\u00E1v\u00E1 se 250 mg nintedanibu 2x denn\u011B, v kombinaci s paclitaxelem a carboplatinou. Ze studi\u00ED III. f\u00E1ze jsou v sou\u010Dasn\u00E9 dob\u011B k dispozici prvn\u00ED v\u00FDsledky studie LUME-Lung 1, kde bylo pozorov\u00E1no v\u00FDznamn\u011B del\u0161\u00ED PFS p\u0159i kombina\u010Dn\u00ED l\u00E9\u010Db\u011B s nintedanibem v porovn\u00E1n\u00ED s placebem, a to jak v cel\u00E9 skupin\u011B nemocn\u00FDch, tak u nemocn\u00FDch s adenokarcinomem a se skvam\u00F3zn\u00EDm karcinomem samostatn\u011B. Celkov\u00E9 p\u0159e\u017Eit\u00ED hodnocen\u00E9 v cel\u00E9 skupin\u011B nemocn\u00FDch bylo rovn\u011B\u017E p\u0159\u00EDzniv\u011B, i kdy\u017E statisticky nev\u00FDznamn\u011B ovlivn\u011Bno pod\u00E1n\u00EDm nintedanibu."@cs . "[A9B82CE0878A]" . . "1"^^ . "RIV/00216208:11150/13:10189880" . "Nintedanib, a new angiokinase inhibitor in the treatment of non-small cell lung cancer"@en . "CZ - \u010Cesk\u00E1 republika" . . . "Nintedanib je peror\u00E1ln\u011B u\u017E\u00EDvan\u00FD inhibitor angiokin\u00E1z, u\u010Dinkuj\u00EDc\u00ED na receptorech pro VEGF typu 1, 2 a 3, PDGF typu \u03B1 a \u03B2, FGF typu 1, 2 a 3, d\u00E1le na receptorech pro FLT3 a skupiny Src. Je tedy ovlivn\u011Bna proliferace a p\u0159e\u017Eit\u00ED t\u0159\u00ED kl\u00ED\u010Dov\u00FDch bun\u011B\u010Dn\u00FDch populac\u00ED z\u00FA\u010Dastn\u011Bn\u00FDch p\u0159i neoangiogenezi - endoteli\u00E1ln\u00EDch bun\u011Bk, pericyt\u016F a bun\u011Bk hladk\u00E9 svaloviny. Pod\u00E1v\u00E1 se 250 mg nintedanibu 2x denn\u011B, v kombinaci s paclitaxelem a carboplatinou. Ze studi\u00ED III. f\u00E1ze jsou v sou\u010Dasn\u00E9 dob\u011B k dispozici prvn\u00ED v\u00FDsledky studie LUME-Lung 1, kde bylo pozorov\u00E1no v\u00FDznamn\u011B del\u0161\u00ED PFS p\u0159i kombina\u010Dn\u00ED l\u00E9\u010Db\u011B s nintedanibem v porovn\u00E1n\u00ED s placebem, a to jak v cel\u00E9 skupin\u011B nemocn\u00FDch, tak u nemocn\u00FDch s adenokarcinomem a se skvam\u00F3zn\u00EDm karcinomem samostatn\u011B. Celkov\u00E9 p\u0159e\u017Eit\u00ED hodnocen\u00E9 v cel\u00E9 skupin\u011B nemocn\u00FDch bylo rovn\u011B\u017E p\u0159\u00EDzniv\u011B, i kdy\u017E statisticky nev\u00FDznamn\u011B ovlivn\u011Bno pod\u00E1n\u00EDm nintedanibu." .